Get regular updates to your inbox.
A seaweed-derived preparation named GV-971 (sodium oligomannate) that has anti-inflammatory effects through the gut-brain axis, delayed the onset and progression of neuromyelitis optica spectrum disorder (NMOSD) in mouse models of the disease, a study shows. The preparation developed by Green Valley Pharmaceuticals is approved in China as an…
HNSA-5487, Hansa Biopharma’s experimental treatment for neuromyelitis optica spectrum disorder (NMOSD) and other autoimmune diseases, safely and effectively reduced the levels of immunoglobulin G (IgG) antibodies — ones involved in the abnormal immune attacks that drive these conditions — in a Phase 1 clinical trial involving healthy volunteers.
In the five years before their first disease attack, people with neuromyelitis optica spectrum disorder (NMOSD) required significantly more doctor’s office visits and hospitalizations than their peers in the general population, a new study from Canada found. The researchers believe these findings point to the presence of an NMOSD…
Uplizna (inebilizumab) treatment markedly reduces the number of several subsets of immune B-cells that are linked to disease relapses in people with neuromyelitis optica spectrum disorder (NMOSD), trial data show. The therapy also lowers levels of the self-reactive antibodies against the AQP4 protein that drive most NMOSD cases,…
Experiencing attacks marked by transverse myelitis, or spinal cord inflammation, significantly increases the chance of worse disability in people with neuromyelitis optica spectrum disorder (NMOSD) patients and the related condition myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Those are the findings of a study analyzing data from a Portuguese national…
Maintenance treatment with rituximab significantly reduced the number of relapses per year in people with neuromyelitis optica spectrum disorder (NMOSD), and it remained effective after patients experienced relapses, according to a study from China. Relapses more frequently occurred within the first year after rituximab initiation, and their frequency decreased…
The risk of losing income increases dramatically within a few years after the onset of neuromyelitis optica spectrum disorder (NMOSD) in patients positive for antibodies against aquaporin-4 (AQP4), compared with the general population. That’s according to a nationwide study in Denmark that also showed AQP4-related NMOSD was strongly associated…
Combining blood-cleaning therapies such as plasma exchange or immunoadsorption with standard steroid treatment can improve recovery outcomes in patients having an attack of neuromyelitis optica spectrum disorder (NMOSD), a study that reported no significant safety concerns shows. The study, “Efficacy and safety of apheresis therapy in AQP4 antibody‐positive…
Nearly all neuromyelitis optica spectrum disorder (NMOSD) patients who start taking Enspryng (satralizumab) are free of relapses after six months, according to interim data from an ongoing post-marketing surveillance study in Japan. With a relapse rate of only 5% over six months, the findings were “comparable or lower…
Age at disease onset and sex ratio — the ratio of males to females — among people with neuromyelitis optica spectrum disorder (NMOSD) are influenced by the proportion of cases with antibodies against aquaporin-4 (AQP4). That’s according to a review study from an international team of researchers that sheds…
Get regular updates to your inbox.